We previously reported the high prevalence of highly penetrant pathogenic variants in BRCA1, BRCA2, PALB2, and TP53 genes in consecutive women presenting with advanced breast cancer at tertiary hospitals in Nigeria, Cameroon, and Uganda [7, 8]. This evidence concerns the gene PALB2 and breast carcinoma.